Form 4: Bristol-Myers Squibb Executive Karin Shanahan Reports Stock Transactions

EVP Karin Shanahan reports acquisition of restricted stock units and adjustments to common stock holdings through a 401(k) plan.

Summary

• Karin Shanahan, EVP at Bristol-Myers Squibb, filed a Form 4 detailing changes in beneficial ownership.
• On November 1, 2024, Shanahan acquired 18,843 restricted stock units (RSUs) that vest in three equal annual installments starting November 1, 2025, and convert into common stock upon vesting.
• Shanahan also reported owning 5,336 shares of common stock directly and 920.24 shares indirectly through the BMS Savings and Investment Program (401(k)).

Sentiment

Score: 6

Explanation: Neutral sentiment as the document is a standard regulatory filing detailing stock transactions. The acquisition of RSUs is generally a positive sign, but it's a routine part of executive compensation.

Positives

• The acquisition of RSUs indicates confidence in the company's future performance.

Future Outlook

The vesting schedule of the restricted stock units suggests a multi-year commitment from the executive.

Industry Context

Form 4 filings are standard practice and provide transparency into executive compensation and stock ownership, which is closely monitored by investors.

Comparison to Industry Standards

• Executive compensation packages including restricted stock units are common in the pharmaceutical industry to align executive interests with shareholder value.
• Companies like Pfizer (PFE) and Merck (MRK) also utilize RSUs as part of their executive compensation plans.
• The vesting schedules are generally comparable to industry norms, often spanning three to five years.

Stakeholder Impact

• Shareholders can monitor executive stock ownership to assess alignment of interests.

Key Dates